| Popis: |
Rajnish Nagarkar,1 Mamillapalli Gopichand,2 Suparna Kanti Pal,3 Ankur Gupta,4,5 Najmuddin Mohd Saquib,4,5 Ganga Sagar,4 Kanury VS Rao,4,5 Zaved Siddiqui,4,5 Imliwati Longkumer6 1Surgical Oncology, HCG Manavta Cancer Centre, Nashik, Maharashtra, India; 2Surgical Oncology, HealthCare Global Enterprises Limited, Vijayawada, India; 3Radiotherapy, Indoriv Clinical, Kolkata, India; 4Research and Development Section, PredOmix Technologies Private Limited, Gurugram, India; 5Research and Development Section, PredOmix Health Sciences Private Limited, Singapore; 6Biochemistry, North East Cancer Hospital and Research Institute, Guwahati, Assam, IndiaCorrespondence: Imliwati Longkumer; Zaved Siddiqui, Email ilongkumer@yahoo.co.in; zaved@predomix.comAbstract: We evaluated the potential relevance of our multi-cancer detection test, OncoVeryx-F, for ovarian cancer screening. For this, we compared its accuracy with that of CA125-based screening. We demonstrate here that, in contrast to CA125-based detection, OncoVeryx-F detected ovarian cancer with very high sensitivity and specificity. Importantly here, Stage I cancers too could be detected with an accuracy of > 98%. Furthermore, again unlike CA 125, the detection accuracy of OncoVeryx-F remained comparable in both Caucasian and South Asian/Indian women. Thus, the robustness and accuracy of OncoVeryx-F, particularly for early-stage detection, underscores its potential utility for ovarian cancer screening.Keywords: CA 125, Oncoveryx-F, OvC, NoC, LC-MS/MS |
